Objective To evaluate the incidence and risk factors for malignancy in Japanese patients with systemic sclerosis (SSc). Methods A cohort of 405 Japanese patients with SSc who visited Kitasato University hospital between 1973 and 2008 was analyzed retrospectively until the end of 2009. The incidence of malignancy was compared with that of the general population, with calculation of the standardized incidence ratio (SIR) and 95% confidence interval (CI). Results The cohort represented 4,787 person-years of total disease duration after the diagnosis of SSc. Of 27 malignancies clinically found, lung cancer (n=10, 37%), especially adenocarcinoma, was the most frequent, followed by breast (n=4, 15%) or gastric (n=3, 11%) cancer. SSc patients with overlapping CTD tended to have less malignancy. Multivariable analysis revealed heart involvement of SSc as a significant risk factor for breast cancer (RR 8.2, 95% CI 1.2-72.8). Other than gastric cancer, the calculated SIRs of malignancies in SSc patients were above 1 (SIR of overall malignancy 1.24, 95% CI 0.77-1.71), even though only lung cancer had a significantly elevated incidence (SIR 5.73,). Every patient with lung cancer had interstitial lung disease (ILD) and every autopsy performed on patients with lung cancer found a primary lesion of lung cancer in their ILD lesion (n=4). Conclusion Lung cancer was significantly frequent in SSc patients, which could develop on the basis of complicated ILD.
Introduction
Systemic sclerosis (SSc) is a chronic, multisystemic and autoimmune disease of which the pathogenesis is unclear. Organ involvement such as scleroderma renal crisis (SRC), interstitial lung disease (ILD) or pulmonary artery hypertension (PAH) contributes to the mortality in SSc patients, but some of these have become treatable through recent advances in medicine. In particular, treatment with angiotensin-converting enzyme inhibitors has dramatically decreased the mortality of SRC, which was the most lethal complication of SSc. Indeed, survival of SSc patients has been improved and the rate of direct SSc-related death has decreased, which suggests that other major causes of death, such as malignancy and infection, are being addressed (1, 2) .
In our previous report, we noted that malignancy was the most frequent cause of death after unknown causes (2) . Therefore, in this study, we evaluated the incidence and risk factors of malignancy with respect to clinical features in Japanese patients with SSc at a single institute.
Materials and Methods
Patients who visited Kitasato University Hospital from 1973 to 2008 regularly, and who showed bilateral symmetrical skin thickening, including those with only sclerodactyly (3), were enrolled in the cohort (n=405), as reported previously (2, 4) . Patients who met the Japanese diagnostic criteria for mixed connective tissue disease (MCTD) were excluded (5) . The data of their clinical features including age, sex, disease duration, outcome, organ involvements, autoantibody profiles, overlap of connective tissue diseases (CTDs), and the detailed type and lesion of malignancies were collected from the medical record or autopsy report. The observation period began from the diagnosis of SSc and terminated at the end of 2009. The cohort included referral patients whose diagnosis of SSc was made by previous doctors, which was confirmed again in our hospital. If a patient died or became lost to follow-up by 2009, the time of death or the last visit to our hospital was the end of observation. Information of malignancy which occurred between the diagnosis of SSc and the first visit to our hospital was taken from referral letters. Nine patients who were lost to followup were excluded from survival analysis. This study was approved by the ethics committee of the Kitasato University Hospital.
Details of the cohort were described previously (2, 4) . In brief, the onset of SSc was defined as that of Raynaud's phenomenon or joint symptoms occurring before skin sclerosis, as well as the characteristic symptoms caused by organ involvement (6) . SSc was classified into diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) according to the skin involvement (7) . Gastrointestinal tract involvement was defined as gastroesophageal reflux disease (GERD), dysphagia, bacterial overgrowth requiring antibiotics, and/or paralytic ileus (8) . Lung involvement was defined as bibasal pulmonary fibrosis detected on chest radiographs or by computed tomography. Heart involvement was defined as a left ventricular ejection fraction of less than 40% measured by echocardiography, conduction disturbance or arrhythmia requiring therapy, or congestive heart failure. SRC was defined by the occurrence of malignant arterial hypertension or rapidly progressive oliguric renal failure without other discernible causes during the course of SSc (9) . Renal involvement was defined as present or past SRC, as well as continuous proteinuria or a glomerular filtration rate of less than 60 mL/min per 1.73 m 2 (10) . PAH was diagnosed from a mean pulmonary arterial pressure of more than 25 mmHg measured directly by right heart catheterization (11), or an estimated pulmonary arterial pressure of more than 35 mmHg calculated from the tricuspid flow velocity by Doppler echocardiography (12) , excluding that secondary to left heart failure. Overlapping systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was diagnosed according to the 1982 or 1987 criteria of the American Rheumatism Association (now American College of Rheumatology), respectively (13, 14) . Sjögren's syndrome was diagnosed according to the 1999 Japanese Ministry of Health and Welfare's diagnostic criteria for Sjögren's syndrome (SjS) (15) . Myositis was defined as inflammation of skeletal muscle associated with a serum creatine kinase level above the normal institutional range. The occurrence of such conditions may have been underestimated because not every patient was examined for each organ involvement or overlapping CTDs.
In the entire cohort of 405 SSc patients, 357 patients were examined for the three anti-ENA antibodies (anti-Scl-70, anti-centromere, and anti-U1-RNP antibody). In the analyses regarding autoantibody, only the 357 patients were investigated and the other patients were excluded.
Statistical Analyses
Between-groups comparison for univariate analysis was conducted using Wilcoxon rank sum test or Kruskal-Wallis test for numerical values, or Fisher's exact test for proportions. Multivariable analysis with multiple logistic regression was carried out to detect risk factors for malignancy. These tests were calculated using Jmp 5.1 (SAS Institute Japan, Tokyo, Japan).
The standardized incidence ratio (SIR) is the ratio between the observed incidence in the cohort of this study and the expected incidence in the comparable age-and sexmatched Japanese population. The incidence of malignancy in the general Japanese population in 1985 or 1999 obtained from the Research Group for Population-based Cancer Registration in Japan (16, 17) was utilized. The 95% confidence interval of an SIR was calculated by regarding the observed number of the incidence of malignancy as a Poisson variable and by obtaining its related 95% interval in statistical tables. Values were expressed as median ± standard error of the mean (SEM), and p values of less than 0.05 were considered significant.
Results
The total and median observation period of the cohort was 4,787 person-years and 10 (range 1 to 46) years, respectively. Of the 405 SSc patients, 376 (92.8%) were females and 29 (7.2%) were males. There were 270 lcSSc (66.6%) and 135 dcSSc (33.3%) patients. By 2009, 310 (76.5%) were survivors, 86 (21.2%) had died, and 9 were lost during follow-up. General features of the cohort concerning the presence or absence of malignancy are shown in Table 1 . The 405 SSc patients showed diverse disease durations ranging from 1 to 59 years. Of the 405 patients in the cohort, 27 malignancies were observed (6.7%, 13 dcSSc and 14 lcSSc) after the diagnosis of SSc, excluding malignancies occurred before the diagnosis of SSc or found at the autopsy. The relation between autoantibodies and malignancy was analyzed in the 357 SSc patients who were examined for the three anti-ENA antibodies. The positive ratios for anti-Scl-70, anti-centromere, and anti-U1-RNP anti- Values are median ± standard error of the mean. *: Nine patients who were lost to followup were excluded from survival analysis. The age at occurrence of malignancy was 57±1.7 years (median ± SEM) and there was no significant difference between types of malignancy (p=0.5103 by Kruskal-Wallis test). The median time interval between the diagnosis of SSc and occurrence of malignancy was 8.0±1.8 years (range 0 to 44), which was not significantly correlated with types of malignancy (p=0.2091).
The frequencies and types of malignancy are shown in Table 2 . Lung cancer (n=10, all female), especially adenocarcinoma, was the most frequent followed by breast (n=4) or gastric cancer (n=3). Only one patient with esophageal cancer had a typical progress, which developed from chronic reflux esophagitis followed by Barrett's esophagus (Barrett's metaplasia) (18) . Multivariable analysis was performed to detect risk factors for malignancy using multiple logistic regression analysis. Clinical factors including organ involvement (skin, gastrointestinal tract, lungs, and heart) and positivity of the three autoantibodies (anti-Scl-70, anti-centromere, and anti-U1-RNP antibody) were employed for the analysis. No factor was found to be significant for overall malignancy, while heart involvement of SSc was correlated with breast cancer (RR 8.2, 95% CI 1.2-72.8). Although lung involvement was not considered a significant risk factor for lung cancer in multivariable analysis, every patient with lung cancer had lung involvement which 50.4% of the cohort had. In addition, autopsies performed on 4 patients with lung cancer confirmed that their primary lesion of lung cancer was in the area of ILD pathologically.
To compare the incidence of malignancies with that of the general population, the SIR was calculated in comparison to an age-and sex-matched Japanese population. As shown in Table 3 , calculated SIRs of malignancies in SSc patients were above 1 (SIR of overall malignancy 1.24, 95% CI 0.77-1.71) except for those of gastric cancer. Even though only lung cancer showed a significantly elevated incidence (SIR 5.73, 95% CI 2.18-9.29), lymphoma also presented a high SIR (4.36).
Discussion
In our previous studies, a cohort of Japanese patients with Standardized incidence ratios (SIR) and 95% confidence intervals (in parentheses) of malignancies. SIR of lung cancer in the entire cohort and female patients were significantly increased. * SIR significantly higher than 1. NA, not applicable.
SSc was retrospectively examined for general features and the relation between organ involvement and autoantibodies (4), as well as the survival and cause of death (2) . In this study, we examined the incidence and risk factors of malignancy regarding clinical features of SSc patients in the same cohort.
The risk of malignancy in SSc patients compared to the general population is controversial. Some studies reported no significant increased risk (19) (20) (21) , similar to our results, while other studies indicated an excess incidence of malignancy with significantly increased SIRs (22) (23) (24) (25) (26) (27) (28) (29) (30) . In SSc patients with long disease duration, it is not rare to develop a malignancy with or without carcinogenic effect of SSc itself or the medication, such as cyclophosphamide. The prevalence of malignancy in Japanese autopsy cases with SSc is reported to range from 12.3 to 14.6% (31) , and it has been increasing because the survival rate of SSc patients has improved and the disease duration has lengthened over time (1) . However, the prevalence of malignancy depends greatly on age and disease duration of the patients. For this reason the SIR analysis was employed to investigate the incidence of malignancy. Although Higuchi et al. mentioned a significant elevated SIR (SIR 5.1, n=43) for cancer in Japanese patents with SSc (26), which was much higher than that of the present estimate (SIR 1.24, n=405), our results were derived from a larger cohort and could represent an overview of Japanese patients with SSc.
This study showed that lung cancer was the most frequent cancer in SSc patients in agreement with a previous study in Japan (32) . The estimate of SIRs demonstrated a high rate of lung cancer in SSc patients compared with an age-and sex-matched Japanese population, in contrast with no increase in overall malignancy. This increased incidence of lung cancer in SSc patients has been generally confirmed (21-25, 27, 29, 30) . Further, association between lung involvement and lung cancer in SSc patients has been established (22, 24, 33, 34) . Indeed, in our cohort every patient with lung cancer had ILD and autopsies detected primary lesions of lung cancer in ILD lesions. Meanwhile, non-SSc patients with ILD also have an increased incidence of lung cancer, indicating a strong potential of ILD, not SSc, to develop lung cancer (35) (36) (37) (38) (39) . In such cases lung cancer might develop on the basis of antecedent ILD, that is, persistent inflammation, fibrosis and dysregulated cytokine signaling in the lung (40) .
In this study, the histopathological type of lung cancer was characterized as predominant adenocarcinoma (including bronchioloalveolar carcinoma), which has often been reported to be the most frequent type (24, 27, 29, 34) . Similarly, adenocarcinoma was the most common type in nonSSc Japanese patients with ILD (36), as well as in the Japanese general population, especially in females (41) . Thus, SSc, as well as ILD has little effect on the histopathological type of lung cancer as that occurring in the general population.
While lung and breast cancer are the two predominant cancers in SSc patients and lung cancer has been established to have an excess SIR, breast cancer showed no increased SIR in this study, as well as most reports (21-23, 25, 27, 28, 30) . The majority of SSc patients consists of middle-aged females in whom the incidence of breast cancer is initially high. Therefore, SSc probably does not contribute to the development of breast cancer. Similarly, gastric cancer was frequent in this study, but had no increased SIR because it is common in the Japanese population. Lymphoma showed a high SIR next to lung cancer, but it did not reach statistical difference. As well as primary SjS, SLE and RA were reported to be the risk factors for lymphoma (42) . The present results support a potential of CTDs for leading to lymphoma, whereas SSc patients with overlapping CTD tended to not develop malignancy. The mechanism of occurrence of lymphoma in patients with CTDs remains to be elucidated.
In contrast to our results, the type of skin involvement of SSc (21, 25) or the presence of autoantibodies such as antiScl-70 antibody (43) and anti-centromere antibody (26) have been reported to be associated with malignancy. This may due to the small sample size of the studies (26, 43) or regional and/or racial differences in the characteristics of the cohort (21, 25) . Regional and/or racial differences in the characteristics of the cohort is supported by the inconsistency in the reports that liver or skin cancer had elevated SIRs, while no patient developed such cancers in our cohort. We detected heart involvement as a risk factor for breast cancer, but the reason is unknown. Our study lacks data on other autoantibodies or clinical factors such as medication and smoking history. It is controversial whether smoking is a risk factor for lung cancer in SSc patients (34, 44) , and should be ascertained. Recent reports indicated the relation between malignancy and anti-RNA polymerase III antibody (45, 46) , which is a characteristic autoantibody in SSc patients. In addition to the limitations of this study derived from the sample size, regional/racial characteristics, or analyzed clinical factors, it should be mentioned that this is a retrospective cohort study in which not every patient took a series of examinations including autoantibody tests or imaging methods to detect each organ involvement or malignancy. It could ignore mild or early comorbidities, leading to a lower estimated prevalence. Entry of the cohort included diagnosis of SSc made before the first visit to our hospital, which could cause a referral bias. A larger prospective cohort and the accumulation of well-defined clinical data are necessary to approach the more detailed and precise relation between SSc and malignancy.
Taken together, malignancy in SSc patients is lifethreatening, but is not so frequent with the exception of lung cancer. Therefore, the carcinogenic effect of SSc per se is considered small or non-specific according to the characteristics of the general population. Our results suggest that, when treating SSc patients, particular attention should be paid to complicated ILD, which can lead to lung cancer.
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